International Journal of Endocrinology最新文献

{"title":"Severe Obesity in Women Can Lead to Worse Memory Function and Iron Dyshomeostasis Compared to Lower Grade Obesity.","authors":"Jessica M V Pino,&nbsp;Vitória F Silva,&nbsp;Marcos Mônico-Neto,&nbsp;Danielle C Seva,&nbsp;Melissa Y Kato,&nbsp;July N Alves,&nbsp;Gabriela C Pereira,&nbsp;Hanna Karen M Antunes,&nbsp;Thales D Galvao,&nbsp;Lia R A Bitterncourt,&nbsp;Sergio Tufik,&nbsp;Lysien I Zambrano,&nbsp;Ana R Dâmaso,&nbsp;Lila M Oyama,&nbsp;David Thivel,&nbsp;Raquel M S Campos,&nbsp;Kil S Lee","doi":"10.1155/2023/7625720","DOIUrl":"https://doi.org/10.1155/2023/7625720","url":null,"abstract":"<p><strong>Objective: </strong>Obesity is one of the modifiable risk factors for dementia. Insulin resistance, the abundance of advanced glycated end-products, and inflammation are some of the mechanisms associated with the lower cognitive performance observed in obesity. This study aims to evaluate the cognitive function of subjects with distinct degrees of obesity, comparing class I and II obesity (OBI/II) to class III obesity (OBIII), and to investigate metabolic markers that can distinguish OBIII from OBI/II. <i>Study Design.</i> This is a cross-sectional study, in which 45 females with BMI varying from 32.8 to 51.9 kg/m² completed a set of 4 cognitive tests (verbal paired-associate test, stroop color, digit span, and Toulouse-Pieron cancellation test) and their plasma metabolites, enzymes, and hormones related to glycemia, dyslipidemia, and liver function, as well as the biomarkers of iron status, were concomitantly analyzed.</p><p><strong>Results: </strong>OBIII showed lower scores in the verbal paired-associate test compared to OBI/II. In other cognitive tests, both groups showed similar performance. OBIII presented a lower iron status compared to OBI/II based on total iron binding capacity, degree of transferrin saturation, hemoglobin, mean corpuscular volume, and mean corpuscular hemoglobin. The levels of indicators for glycemia, liver function, and lipid metabolism were similar in both groups. Analysis of plasma metabolites showed that OBIII had lower levels of pyroglutamic acid, myoinositol, and aspartic acid and higher levels of D-ribose than OBI/II.</p><p><strong>Conclusion: </strong>Iron is an essential micronutrient for several metabolic pathways. Thus, iron dyshomeostasis observed in severe obesity may aggravate the cognitive impairment by altering metabolic homeostasis and enhancing oxidative stress. These findings can contribute to searching for biomarkers that indicate cognitive performance in the population with obesity.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9725804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Granulocytopenia in Patients with Graves' Disease Receiving Antithyroid Drugs.","authors":"Jiaxi Li,&nbsp;Xiaowen Zhang,&nbsp;Lintong Li,&nbsp;Qiaoling Zhu,&nbsp;Weihong Ge,&nbsp;Cheng Ji","doi":"10.1155/2023/9935195","DOIUrl":"https://doi.org/10.1155/2023/9935195","url":null,"abstract":"<p><strong>Objective: </strong>To study the risk factors for granulocytopenia caused by antithyroid drugs.</p><p><strong>Methods: </strong>Patients who were diagnosed with Graves' hyperthyroidism and regularly treated with antithyroid drugs (ATDs) from January 2010 to July 2022 at Nanjing Drum Tower Hospital, aged >18 years, were selected for general information and laboratory tests and divided into two groups according to the occurrence of granulocytopenia. Independent risk factors for the development of granulocytopenia in patients treated with ATDs were analyzed using one-way and multiway logistic regression analyses, and the predictive value of each index was evaluated using the receiver operating characteristic (ROC) curve and the area under the curve (AUC).</p><p><strong>Results: </strong>A total of 818 patients were enrolled, of which 95 developed granulocytopenia. Univariate analysis revealed that sex, white blood cell (WBC) counts, neutrophil-to-lymphocyte ratio (NLR), glutamic-pyruvic transaminase (ALT), aspartate transaminase (AST), free triiodothyronine (FT3), free thyroxine (FT4), and thyroid stimulating hormone (TSH) before medication were risk factors for ATD-induced granulocytopenia (<i>P</i> < 0.05). The abovementioned indicators were taken as independent variables, and multivariate logistic regression analysis showed that female sex, higher ALT levels before medication, and lower NLR and WBC levels were independent risk factors for granulocytopenia using ATDs (<i>P</i> < 0.05). ROC curve analysis showed that sex, NLR, ALT, and WBC count had significant predictive values (<i>P</i> < 0.05), and NLR and WBC count had higher predictive values (AUC = 0.916 and 0.700, respectively).</p><p><strong>Conclusion: </strong>Sex, NLR, ALT, and WBC were the main risk factors for granulocytopenia in patients with ATD.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9737945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Growth Hormone on Adult Human Gonads: Action on Reproduction and Sexual Function.","authors":"Xin-Yi Zhou,&nbsp;Jia-Ni Ma,&nbsp;Ya-Yin Shen,&nbsp;Xue-Rui Xie,&nbsp;Wei Ren","doi":"10.1155/2023/7492696","DOIUrl":"https://doi.org/10.1155/2023/7492696","url":null,"abstract":"<p><p>Growth hormone (GH), which is commonly considered to be a promoter of growth and development, has direct and indirect effects on adult gonads that influence reproduction and sexual function of humans and nonhumans. GH receptors are expressed in adult gonads in some species including humans. For males, GH can improve the sensitivity of gonadotropins, contribute to testicular steroidogenesis, influence spermatogenesis possibly, and regulate erectile function. For females, GH can modulate ovarian steroidogenesis and ovarian angiogenesis, promote the development of ovarian cells, enhance the metabolism and proliferation of endometrial cells, and ameliorate female sexual function. Insulin-like growth factor-1 (IGF-1) is the main mediator of GH. <i>In vivo</i>, a number of the physiological effects of GH are mediated by GH-induced hepatic IGF-1 and local IGF-1. In this review, we highlight the roles of GH and IGF-1 in adult human gonads, clarify potential mechanisms, and explore the efficacy and the risk of GH supplementation in associated deficiency and assisted reproductive technologies. Besides, the effects of excess GH on adult human gonads are discussed as well.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9309526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MAFLD in Patients with Cushing's Disease Is Negatively Associated with Low Free Thyroxine Levels Rather than with Cortisol or TSH Levels.","authors":"Kuangyang Chen,&nbsp;Lijiao Chen,&nbsp;Jiarong Dai,&nbsp;Hongying Ye","doi":"10.1155/2023/6637396","DOIUrl":"https://doi.org/10.1155/2023/6637396","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to analyze the clinical characteristic of metabolic associated fatty liver disease (MAFLD) in patients with active Cushing's disease (CD) and determine associations of thyroid hormones with MAFLD.</p><p><strong>Methods: </strong>Patients with active CD were included in this cross-sectional study. All subjects were assessed for hepatic steatosis by abdominal ultrasonography and thyroid functions. Demographic and clinical characteristic parameters were collected for correlation analysis and logistic analysis.</p><p><strong>Results: </strong>290 individuals with active CD were included in Huashan hospital from January 2014 to February 2022. We found that the prevalence of CD with MAFLD was 33.79%. The MAFLD group had a lower level of FT4 and a higher level of FT3/FT4 but no difference in levels of cortisol, 24 h UFC, TSH, TT4, TT3, and FT3. Correlation analysis showed positive associations of TSH, TT4, TT3, FT3, and FT3/FT4 with BMI. In age-, BMI-, sex-, cortisol-, and 24 h UFC-adjusted analysis, FT4 was independently associated with MAFLD in patients with CD. This association remained similar even after adjusting for the presence of metabolic syndrome components.</p><p><strong>Conclusion: </strong>Lower FT4 levels were associated with higher risk of MAFLD in patients with CD. FT4 may be used as a helpful indicator to predict MAFLD and provide novel ideas for the treatment of MAFLD in patients with CD in the future.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9388679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Variants of <i>SIRT1</i> Gene Promoter in Type 2 Diabetes.","authors":"Shuchao Pang,&nbsp;Zhengjun Zhang,&nbsp;Yu Zhou,&nbsp;Jie Zhang,&nbsp;Bo Yan","doi":"10.1155/2023/6919275","DOIUrl":"https://doi.org/10.1155/2023/6919275","url":null,"abstract":"<p><p>Type 2 diabetes (T2D) is a highly heterogeneous and polygenic disease. To date, genetic causes and underlying mechanisms for T2D remain unclear. SIRT1, one member of highly conserved NAD-dependent class III deacetylases, has been implicated in many human diseases. Accumulating evidence indicates that SIRT1 is involved in insulin resistance and impaired pancreatic <i>β</i>-cell function, the two hallmarks of T2D. Thus, we speculated that altered SIRT1 levels, resulting from the genetic variants within its regulatory region of <i>SIRT1</i> gene, may contribute to the T2D development. In this study, the <i>SIRT1</i> gene promoter was genetically analyzed in T2D patients (<i>n</i> = 218) and healthy controls (<i>n</i> = 358). A total of 20 genetic variants, including 7 single-nucleotide polymorphisms (SNPs), were identified. Five heterozygous genetic variants (g.4114-15InsA, g.4801G > A, g.4816G > C, g.4934G > T, and g.4963_64Ins17bp) and one SNP (g.4198A > C (rs35706870)) were identified in T2D patients, but in none of the controls. The frequencies of two SNPs (g.4540A > G (rs3740051) (OR: 1.75, 95% CI: 1.24-2.47, <i>P</i> < 0.001 in dominant genetic model) and g.4821G > T (rs35995735)) (OR: 3.58, 95% CI: 1.94-6.60, <i>P</i> < 0.001 in dominant genetic model) were significantly higher in T2D patients. Further association and haplotype analyses confirmed that these two SNPs were strongly linked, contributing to the T2D (OR: 1.442, 95% CI: 1.080-1.927, <i>P</i> < 0.05). Moreover, most of the genetic variants identified in T2D were disease-specific. Taken together, the genetic variants within <i>SIRT1</i> gene promoter might contribute to the T2D development by altering SIRT1 levels. Underlying molecular mechanism needs to be further explored.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10660546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factor Analysis and Prediction of Severe Hypocalcemia after Total Parathyroidectomy without Auto-Transplantation in Patients with Secondary Hyperparathyroidism.","authors":"Chenchen He,&nbsp;Yibing Zhang,&nbsp;Longfei Li,&nbsp;Guangming Cheng,&nbsp;Wei Zhang,&nbsp;Yufu Tang,&nbsp;Chunhui Wang","doi":"10.1155/2023/1901697","DOIUrl":"https://doi.org/10.1155/2023/1901697","url":null,"abstract":"<p><strong>Objective: </strong>Our study aimed to develop and validate a nomogram to predict severe hypocalcemia (SH) before total parathyroidectomy (TPTX) without auto-transplantation in patients with secondary hyperparathyroidism.</p><p><strong>Methods: </strong>A total of 299 consecutive patients who underwent TPTX without transplantation for secondary hyperparathyroidism were selected from the General Hospital of Northern Theater Command between January 2013 and December 2021. Of these, patients who underwent surgery between January 2013 and December 2020 formed the training cohort (<i>n</i> = 208) to develop a nomogram, and those who underwent surgery thereafter formed the validation cohort (<i>n</i> = 91) to validate the performance of this nomogram. Univariate and multivariate logistic regression analyses were used to identify the risk factors associated with SH, and then, a nomogram was constructed.</p><p><strong>Results: </strong>The incidence of postoperative SH was 27.9% and 35.2% in the training and validation cohorts, respectively. The preoperative factors associated with SH were younger age, lower serum calcium (Ca) level, higher intact parathyroid hormone (iPTH) level, and higher serum alkaline phosphatase (ALP) level. Incorporating these 4 factors, the nomogram achieved good concordance indexes of 0.866 (95%CI, 0.816-0.916) and 0.867 (95% CI, 0.793-0.941) in predicting SH in the training and validation cohorts, respectively, and had well-fitted calibration curves. The positive predictive values of the nomogram were 64.7% (54.1%-78.4%) and 75.0% (58.6%-88.5%), and negative predictive values of the nomogram were 90.0% (82.9%-93.6%) and 86.4% (73.5%-94.0%) for the training and validation cohorts, respectively.</p><p><strong>Conclusions: </strong>We developed and validated a nomogram for the prediction of SH in patients who underwent TPTX without auto-transplantation for secondary hyperparathyroidism. Our nomogram may facilitate the identification of high-risk SH in patients after TPTX and optimization of preoperative decision-making.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10678087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-, Sex-, and Puberty-Associated Reference Intervals for Lipid Profile in Iranian Children and Adolescents.","authors":"Nima Montazeri-Najafabady,&nbsp;Mohammad Hossein Dabbaghmanesh,&nbsp;Naeimehossadat Asmarian,&nbsp;Homeyra Rais Pour","doi":"10.1155/2023/9143234","DOIUrl":"https://doi.org/10.1155/2023/9143234","url":null,"abstract":"<p><p>Childhood dyslipidemia is considered a major worldwide health issue. Identification of children with dyslipidemia is notably essential for healthcare providers in establishing and releasing recommendations for the management and prevention of future CVD. In the present study, we provided reference values for the lipid profile from Kawar (a city in the south of Iran) cohort of healthy children and adolescents aged 9-18 years. 472 subjects (234 girls and 238 boys) contributed to the current prospective cohort study using a systematic random sample stratified by age. Fasting lipid levels were measured by enzymatic reagents. Dual-energyX-ray absorptiometry (DEXA) was used to evaluate puberty based on the Tanner stages. LMS Chart Maker and Excel software were used to construct the gender-specific reference plots showing the 3, 10, 25, 50, 75, 90, and 97th percentiles of BMI, cholesterol, TG, HDL, TC, LDL, and non-HDL. The outcomes revealed that concentrations of TC, LDL, and non-HDL were drastically greater in girls as compared to boys. TG increased with age in both genders, while HDL, TC, LDL, and non-HDL declined. We also observed that puberty was associated with higher lipid values in boys and girls except for TG in boys. Our study prepared age- and sex-specific reference intervals for the lipid profile in Iranian children and adolescents. Converted to age and gender percentiles, these reference intervals are expected to serve as an effective and consistent tool for doctors to identify dyslipidemia among children and adolescents.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9396424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ginsenoside Rg1 Improves Inflammation and Autophagy of the Pancreas and Spleen in Streptozotocin-Induced Type 1 Diabetic Mice.","authors":"Yi Zong,&nbsp;Weihua Yu,&nbsp;Hanghang Hong,&nbsp;Zhiqiang Zhu,&nbsp;Wenbo Xiao,&nbsp;Kewu Wang,&nbsp;Guoqiang Xu","doi":"10.1155/2023/3595992","DOIUrl":"https://doi.org/10.1155/2023/3595992","url":null,"abstract":"<p><strong>Background: </strong>Ginsenoside Rg1 (Rg1) is one of the key bioactive components of the precious Traditional Chinese Medicine that has been used to treat diabetes in China. Ginsenosides have been reported to protect diabetics from tissue damage, inflammation, and insulin resistance. Type 1 diabetes (T1D) is an organ-specific autoimmune disease that occurred frequently among adolescents over the world, its development was related to inflammation and <i>β</i>-cells immunodeficiency. The aim of this study is to explore the biological mechanism of Rg1 on inflammation and autophagy of <i>β</i>-cells in T1D and its therapeutic potential.</p><p><strong>Methods: </strong>The model of T1D mice was established by injecting Streptozotocin (STZ) (55 mg/kg) or citric acids once a day for 5 days and from the fourth day of injection, mice were administered with Rg1 (20 mg/kg) or saline by gavage once a day for 12 days. Hematoxylin-eosin staining, immunofluorescence, ELISA, quantitative real-time PCR, and Western blot were used to observe the histopathological changes, inflammatory factor levels, and autophagy markers after administration of ginsenoside Rg1.</p><p><strong>Results: </strong>Compared to the T1D mice, Rg1 improved the weight (<i>p</i> < 0.05) and blood glucose (<i>p</i> < 0.01) of mice, advanced the injury and apoptosis of <i>β</i>-cells in islets (<i>p</i> < 0.01), and markedly inhibited the protein expression degrees of CD45, CXCL16, ox-LDL, and TF in the pancreas and spleens (<i>p</i> < 0.01), also activated the degrees of insulin in serum (<i>p</i> < 0.01). Besides, in T1D mice' pancreas and spleen, Rg1 markedly repressed the IL-1<i>β</i>, TNF-<i>α</i>, and NOS2 mRNA levels (<i>p</i> < 0.05 or <i>p</i> < 0.01), inhibited the CXCL16, NF-<i>κ</i>B, and TF proteins (<i>p</i> < 0.05 or <i>p</i> < 0.01), while elevating the ratio of LC3 II/I (<i>p</i> < 0.01) and P62 (<i>p</i> < 0.05) protein level.</p><p><strong>Conclusions: </strong>This study proved that Rg1 protected mice against T1D possibly by improving islet injury and tissue inflammation, raising serum insulin, and tissue autophagy marker.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9523224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between the Severity of Metabolic Dysfunction-Associated Fatty Liver Disease and Serum Uric Acid to Serum Creatinine Ratio.","authors":"Jing Liu,&nbsp;Hongye Peng,&nbsp;Che Wang,&nbsp;Yutong Wang,&nbsp;Rongrui Wang,&nbsp;Jixiang Liu,&nbsp;Tianhui Zhou,&nbsp;Shukun Yao","doi":"10.1155/2023/6928117","DOIUrl":"https://doi.org/10.1155/2023/6928117","url":null,"abstract":"<p><strong>Purpose: </strong>As one of the most common chronic liver diseases, metabolic dysfunction-associated fatty liver disease (MAFLD) had different prognoses between mild and moderate-severe levels. Serum uric acid to serum creatinine ratio (sUA/Cr) can reflect the overall metabolic status of the body. To explore a convenient indicator to screen MAFLD and distinguish the severity of the disease, this study analyzed the correlation between sUA/Cr and the severity of MAFLD.</p><p><strong>Methods: </strong>228 participants were enrolled and divided into 2 groups, including mild MAFLD and non-MAFLD group and moderate-severe MAFLD group, based on liver/spleen computed tomography (CT) ratios. The correlations between sUA/Cr and the severity of MAFLD were analyzed by logistic and linear regression. Receiver operating characteristics (ROCs) analyzed the predictive ability of sUA/Cr for the severity of MAFLD expressed by the area under curve (AUC).</p><p><strong>Results: </strong>The level of sUA/Cr was higher in themoderate-severe MAFLD group than mild MAFLD and non-MAFLD group (6.14 ± 1.55 vs. 5.51 ± 1.19, <i>P</i> = 0.008). After adjustment for confounders, the correlation analysis showed that patients with elevated sUA/Cr had a higher risk of moderate-severe MAFLD (OR: 1.350, <i>P</i> = 0.036). A higher sUA/Cr level was associated with lower liver CT values (<i>β</i> = -0.133, <i>P</i> = 0.039) and liver/spleen CT ratio (<i>β</i> = -0.154, <i>P</i> = 0.016). sUA/Cr had the ability to discriminate the severity of MAFLD (AUC: 0.623).</p><p><strong>Conclusion: </strong>sUA/Cr was positively associated with the risk of moderate-severe MAFLD and had the predictive ability to discriminate the moderate-severe MAFLD from mild MAFLD and non-MAFLD. The sUA/Cr level was suggested to be monitored and controlled in the screening and treatment of MAFLD.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10587421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glutathione-S-Transferase <i>p</i>1 Gene Promoter Methylation in Cell-Free DNA as a Diagnostic and Prognostic Tool for Prostate Cancer: A Systematic Review and Meta-Analysis.","authors":"Jinghe Ye,&nbsp;Mao Wu,&nbsp;Long He,&nbsp;Peng Chen,&nbsp;Hongtao Liu,&nbsp;Hongwei Yang","doi":"10.1155/2023/7279243","DOIUrl":"https://doi.org/10.1155/2023/7279243","url":null,"abstract":"<p><strong>Background: </strong>Promoter methylation of glutathione-S-transferase <i>p</i>1 (GSTP1) is related to the occurrence of prostate cancer (PCa), but reports are inconsistent about the accuracy of GSTP1 promoter methylation in PCa diagnosis and prognosis. Therefore, we systematically evaluated the diagnostic and prognostic value of GSTP1 promoter methylation in PCa.</p><p><strong>Methods: </strong>The PubMed, EMBASE, Web of Science, and PMC databases were searched for all relevant studies from the date of inception to November 31, 2021. We compared differences in the incidence of GSTP1 promoter methylation in cfDNA between prostate cancer patients and controls. The odds ratio (OR) and hazard ratio (HR) were used as effect sizes, and the result of each effect size is expressed as a 95% confidence interval (95% CI).</p><p><strong>Results: </strong>Our meta-analysis showed that the combined sensitivity and specificity of GSTP1 promoter methylation in cfDNA for the diagnosis of prostate cancer were 0.37 (95% CI = 0.23, 0.53) and 0.97 (95% CI = 0.88, 0.99), respectively. The area under the curve (AUC) with 95% CI was 0.78 (95% CI = 0.75, 0.82). For prognostic variables, hypermethylation of GSTP1 was associated with shorter survival in PCa (HR = 2.57, 95% CI = 1.30, 5.10), with statistical significance in between-study heterogeneity (<i>I</i> ² = 72%, <i>P</i>=0.006). The results of the subgroup analysis indicated that the heterogeneity of studies may be due to differences in the observed indicators.</p><p><strong>Conclusions: </strong>The results of the meta-analysis substantiate the high specificity of promoter methylation of GSTP1 in cfDNA for the diagnosis of prostate cancer, and it may be used to more precisely evaluate the prognosis of patients with prostate cancer. It may be helpful for the early detection of prostate cancer, but it still must be combined with traditional prostate-specific antigen (PSA) or other methylated genes to accomplish this goal.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10665942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}